安进公司 AMGN 深 沪
等待开盘 06-25 09:30:00 美东时间
354.11
+7.100
+2.05%
华盛通- 最 高354.415
- 今 开348.00
- 成交量 106.29万股
- 最 低 346.00
- 昨 收 347.01
- 总市值 1911.16亿
- 52周最高 388.77
- 市盈率 静 24.89
- 换手率 0.20%
- 52周最低 262.35
- 委 比 -92.00%
- 总股本 5.40亿
- 历史最高 388.77
- 量 比 0.29
- 振 幅 2.43%
- 历史最低 -30.959
- 每 手 1
- 风险率 32.33%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多安进第一季度最新动态推动目标价升至303美元 维持中性评级
瑞穗证券分析师萨利姆·赛义德完成对安进公司（股票代码AMGN）第一季度业绩的复盘、更新估值模型后，将该股目标价从295美元上调至303美元，对安进的原有评级仍维...
06-24 21:50
Biotech breakout: iShares Biotechnology ETF hits all-time high
The biotechnology sector continued its advance on Tuesday, with the iShares Biotechnology ETF (IBB) reaching a record intraday high of $179.95 as investor interest in the industry remained strong. The...
06-24 02:52
生物类似药正成为安进公司增长叙事的核心支柱吗
安进（AMGN）当前为全球生物类似药领域领军企业，管线覆盖肿瘤、炎症及罕见病三大领域，生物类似药业务在公司营收增长战略中的权重持续提升。其早期生物类似药受行业竞...
06-23 22:58
Organon and Henlius launch Prolia and Xgeva biosimilars in Canada
Organon Canada (OGN) and Shanghai Henlius Biotech on Tuesday announced the Canadian launch of Bildyos (denosumab injection) and Tuzemty (denosumab injection), biosimilars to Prolia and Xgeva, respecti...
06-23 18:28
FACTBOX-Major deals involving US drugmakers and biotechs over the past decade
FACTBOX-Major deals involving US drugmakers and biotechs over the past decade Adds AbbVie deal June 22 (Reuters) - AbbVie ABBV.N has agreed to buy biotech Apogee Therapeutics APGE.O for $10.9 billion in cash, as the U.S. drugmaker builds its next-generation immunology pipeline. The move adds to a gr
06-22 19:46
Less Volume, More Premium: Post-Ozempic Economics Are Killing The Quantity Model
For years, the average American weight grew alongside the economy, reaching an obesity rate of nearly 40%. Yet, with the popularization of GLP-1 medications, analysts and academics are examining a completely new angle – what happens when millions of people suddenly want smaller lunches? With more th...
06-22 19:15
Analysts’ Top Healthcare Picks: Dr Reddy’s Laboratories (RDY), Amgen (AMGN)
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts jus...
06-18 19:20
J&J avoiding GLP-1 space to focus on cancer drugs
Johnson & Johnson (JNJ) CEO Joaquin Duato says his company has no plans to venture into the fast-growing market for GLP-1 obesity drugs and will instead focus on treatments for conditions such as canc...
06-18 00:20
